Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression

PLoS ONE

Volumn 2, Issue 6, 2007, Pages

  Hardee, Matthew E ^a   Cao, Yiting ^a   Fu, Ping ^a   Jiang, Xiaohong ^a   Zhao, Yulin ^a   Rabbani, Zahid N ^a   Vujaskovic, Zeljko ^a   Dewhirst, Mark W ^a   Arcasoy, Murat O ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; FLUORESCENT DYE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; FEMALE; HISTOPATHOLOGY; HYPOXEMIA; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; RAT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DISEASE COURSE; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; SKIN; VASCULARIZATION;

MUS; MUS MUSCULUS; RODENTIA;

ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; IMMUNOENZYME TECHNIQUES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RATS; RECEPTORS, ERYTHROPOIETIN; SKIN;

EID: 35148857257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000549     Document Type: Article

References (51)

1. Huang Q, Shan S, Braun RD, Lanzen J, Anyrhambatla G, et al. (1999) Noninvasive visualization of tumors in rodent dorsal skin window chambers. Nat Biotechnol 17: 1033-1035.
2. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, et al. (2000) Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92: 143-147.
3. Folkman J (2000) Incipient angiogenesis. J Natl Cancer Inst 92: 94-95.
4. Cao Y, Li CY, Moeller BJ, Yu D, Zhao Y, et al. (2005) Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 65: 5498-5505.
5. Shan S, Robson ND, Cao Y, Qiao T, Li CY, et al. (2004) Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. Faseb J 18: 326-328.
6. Folkman J (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607.
7. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339.
8. Henke M, Laszig R, Rube C, Schafer U, Haase KD, et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260.
9. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, et al. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972.
10. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, et al. (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24: 4708-4713.
11. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, et al. (2007) Randomized, double-blind, placebo-controlled trial or crythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032.
12. Lester RD, Jo M, Campana WM, Gonias SL (2005) Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 280: 39273-39277.
13. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, et al. (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5: 347-355.
14. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, et al. (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66: 135-145.
15. Gewirtz DA, Di X, Walker TD, Sawyer ST (2006) Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res 12: 2232-2238.
16. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, et al. (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93: 2627-2636.
17. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64: 326-333.
18. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, et al. (2004) Erythropoietin regulates endothelial progenitor cells. Blood 103: 921-926.
19. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H (2004) The role of erythropoietin in regulating angiogenesis. Dev Biol 276: 101-110.
20. Yasuda Y, Masuda S, Chikuma M, Inoue E, Nagao M, et al. (1998) Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273: 25381-25387.
21. Haroon ZA, Amin K, Jiang X, Arcasoy MO (2003) A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163: 993-1000.
22. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, et al. (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353: 782-792.
23. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, et al. (2001) Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84: 836-843.
24. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, et al. (2002) Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23: 1797-1805.
25. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, et al. (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021-1029.
26. Tovari J, Gilly R, Raso E, Paku S, Bereczky B, et al. (2005) Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemptherapy in human xenograft models. Cancer Res 65: 7186-7193.
27. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, et al. (1998) Inhibition of tumor growth by targeting tumor endodielium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9: 49-58.
28. Yoshimura A, Longmore G, Lodish HF (1990) Point mutation in the exoplastic domain of the erythropoietin receptor resulting-in hormone-independent activation and tumorigenicity, Nature 348: 647-649.
29. Longmore GD, Lodish HF (1991) An activating mutation in the routine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. Cell 67: 1089-1102.
30. Pharr PN, Hankins D, Hofbauer A, Lodish HF, Longmore GD (1993) Expression of a constitutively active erythropoietin receptor in primary hematopoietic progenitors abrogates erythropoietin dependence and enhances erythroid colony-forming unit, erythroid burst-forming unit, and granulocyte/macrophage progenitor growth. Proc Natl Acad Sci U S A 90: 938-942.
31. Longmore GD, Pharr PN, Lodish HF (1994) A constitutively activated erythropoiein receptor stimulates proliferation and contributes to transformation of multipotent, committed monerythroid and crythroid progenitor cells. Mol Cell Biol 14: 2265-2277.
32. Burns S, Arcasoy MO, Li L, Kurian E, Selander K, et al. (2002) Purification and characterization of the wast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis. Blood 99: 4400-4405.
33. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, et al. (2006) Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 5: 356-361.
34. Shikama Y, Barber DL, D'Andrea AD, Sieff CA (1996) A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoictic cell lines. Blood 88: 455-464.
35. Longmore GD, You Y, Molden J, Liu KD, Mikami A, et al. (1998) Redundant and selective roles for erythropoietin receptor tyrosines in erythropoiesis in vivo. Blood 91: 870-878.
36. Moucadel V, Constantinescu SN (2005) Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. J Biol Chem 280: 13364-13373.
37. Miura Y, Miura O, Ihle JN, Aoki N (1994) Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 269: 29962-29969.
38. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007.
39. Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, et al. (2003) Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 63: 6162-6165.
40. Hardee ME, Kirkpatick JP, Shan S, Snyder SA, Vujaskovic Z, et al. (2005) Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 93: 1350-1355.
41. Menon MP, karur V, Bogacheva O, Bogachev O, Cuctara, B, et al. (2006) Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest 116: 683-694.
42. Bergers G, Javaherian K, Lo KM, Folkman J, Hanalum D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
43. Digicaylioglu M, Lipton SA (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641-647.
44. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, et al. (2002) HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 8: 718-724.
45. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, et al. (2005) Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. Faseb J 19: 1323-1325.
46. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242.
47. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101: 14907-14912.
48. Matthews DJ, Topping RS, Cass RT, Giebel LB (1996) A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci U S A 93: 9471-9476.
49. Qin H, Belanger A, Yoon HW, Bunn HF,(1998) Homodimerization restores biologica activity to an inactive erythropoietin mutant. J Biol Chem 273: 11173-11176.
50. Arcasoy MO, Karayal AF, Segal HM, Sinning JG, Forget BG (2002) A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. Blood 99: 3066-3069.
51. Arcasoy MO, Romana M, Fabry ME, Skarpidi E, Nagel RL, et al. (1997) High levels of human gamma-globin gene expression in adult mice carrying a transgene of deletion-type hereditary persistence of fetal hemoglobin. Mol Cell Riol 17: 2076-2089.